12:00 AM
 | 
May 13, 2013
 |  BC Week In Review  |  Clinical News  |  Regulatory

Depakote divalproex regulatory update

FDA contraindicated valproate products, including all formulations of AbbVie's Depakote divalproex, to prevent migraines in pregnant women after data from the agency's Neurodevelopmental Effects of Antiepileptic Drugs...

Read the full 115 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >